AUTHORS
Surbhi Sidana, MD, Alexandria Jensen, Phd2, Saurabh Zanwar, MBBS, MD3, Hitomi Hosoya, MD, PhD4, Danai Dima, MD5, Noa Biran, MD6, Emily C. Liang, MD7, Lekha Mikkilineni, MD, MA8, Mahmoud R. Gaballa, MD9, Susan Bal, MD10, Gliceida Galarza Fortuna, MD11, Christoph Schaefers, MD12, Christopher J. Ferreri, MD13, Shonali Midha, MD14, Francesca Cottini, MD15, Ashley Rosko, MD16, Binoy Yohannan, MD17, Veronika Bachanova, MD, PhD18, David Iberri, MD19, Vanna Hovanky20, Megan M Herr, PhD21, Chenyu Lin, MD22, Omar Castenada23, Melinda Tan, MD24, Malvika Gupta, MD25, Meera Mohan, MD, MS26, Mackenzie Maberry, MD27, Jennifer Ann Kanakry, MD28, Karen Sweiss, PharmD29, Ariel Grajales-Cruz, MD30, Ciara Louise L Freeman, MD, PhD31, Frederick L. Locke, MD32, James A Davis, PharmD, BCOP33, Marcus Geer, MD34, Hira Mian, MD35, Nisha Joseph, MD36, Sneha Purvey, MD37, Asya Varshavsky, MD38, Aimaz Afrough, MD39, Cindy Varga, MD,BSc40, Kenneth H. Shain, MD, PhD41, Andrew J. Portuguese, MD42, Doug W. Sborov, MD, MS43, Timothy O'Brien, MD44, Shaji Kumar, MD45, Rahul Banerjee, MD46, Krina Patel Jr, MD, MSc47, Ran Reshef, MD, MSc48, Doris K. Hansen, MD49, Yi Lin Jr, MD, PhD50
AFFILIATIONS
1 Stanford University School of Medicine, Palo Alto, California, United States
2 Stanford University School of Medicine, Palo Alto, California, United States
3 Mayo Clinic Conprehensive Cancer Center, Rochester, Minnesota, United States
4 Cedars Sinai Medical Center, Los Angeles, California, United States
5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
6 Quest Diagnostics John Theurer Cancer Center - Oncology Center HUMC, Hackensack, New Jersey, United States
7 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
8 Stanford University School of Medicine, Palo Alto, California, United States
10 University of Alabama at Birmingham, Birmingham, Alabama, United States
11 Huntsman Cancer Institute, Salt Lake City, Utah, United States
12 Mayo Clinic Conprehensive Cancer Center, Rochester, Minnesota, United States
13 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 The Ohio State University Medical Center, Columbus, Ohio, United States
16 The Ohio State University Medical Center, Columbus, Ohio, United States
17 University of Minnesota, Minneapolis, Minnesota, United States
18 University of Minnesota, Minneapolis, Minnesota, United States
19 Stanford University School of Medicine, Palo Alto, California, United States
20 Stanford University School of Medicine, Palo Alto, California, United States
21 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
22 Duke Cancer Center North Durham, Durham, North Carolina, United States
23 Moffitt Cancer Center, Tampa, Florida, United States
24 Mayo Clinic Conprehensive Cancer Center, Rochester, Minnesota, United States
25 Mayo Clinic Conprehensive Cancer Center, Rochester, Minnesota, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 Georgetown University Medical Center, Washington, District of Columbia, United States
29 University of Illinois Chicago, Chicago, Illinois, United States
30 Moffitt Cancer Center, Tampa, Florida, United States
31 Moffitt Cancer Center, Tampa, Florida, United States
32 Moffitt Cancer Center, Tampa, Florida, United States
33 Medical University of the South Carolina, Charleston, South Carolina, United States
34 University of Michigan, Ann Arbor, Michigan, United States
35 McMaster University, Hamilton, Ontario, Canada
36 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
37 Virginia Commonwealth University, Richmond, Virginia, United States
38 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
39 UT Southwestern Medical Center, Dallas, Texas, United States
40 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
41 Moffitt Cancer Center, Tampa, Florida, United States
42 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
43 Huntsman Cancer Institute, Salt Lake City, Utah, United States
44 UH Seidman Cancer Center, Cleveland, Ohio, United States
45 Mayo Clinic Conprehensive Cancer Center, Rochester, Minnesota, United States
46 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
47 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
48 Columbia Herbert Irving Comprehensive Cancer Center, New York, New York, United States
49 Moffitt Cancer Center, Tampa, Florida, United States
50 Mayo Clinic Conprehensive Cancer Center, Rochester, Minnesota, United States
ABSTRACT
Introduction: Cilta-cel, a BCMA-directed CAR-T therapy, produces deep and durable responses in patients (pts) with RRMM, though many pts eventually relapse. Optimal MM management after CAR-T relapse remains unclear, particularly regarding the choice of bispecific antibodies (BsAb) over other treatment modalities or the benefit of targeting non-BCMA antigens.
Methods: In this multicenter study from 23 sites of the US MM Immunotherapy Consortium, we evaluated the outcomes with subsequent lines of therapy (sLOT) following relapse after cilta-cel, focusing on overall response rates (ORR) and progression-free survival (PFS). PFS denotes PFS with index cilta-cel, PFS-1 is PFS with 1st sLOT and PFS-2 is PFS with 2nd sLOT. We assessed whether treatment modality, antigen target, timing of relapse and disease-related factors influenced outcomes with sLOT.
Results: Among 1793 pts receiving cilta-cel from 2022-2025, 395 relapsed; 323 received a sLOT and comprise this study population, of whom nearly half (n=168) received a 2nd sLOT. Among 72 pts with relapse but no sLOT, 43 (59%) died from MM within a median of 37 days.
Median age at cilta-cel infusion was 62 years, pts were 58% male, 16% Black, 56% had high-risk cytogenetics and median LOT before cilta-cel was 4 (range: 1-23). Median PFS with cilta-cel was 34.8 months (mo). Median follow-up after 1st sLOT was 12 mo and after 2nd sLOT was 9.7 mo.
BsAb were used in the majority of 1st sLOT (61%, n=197), with GPRC5D BsAb being the preferred regimen (38%, n=124), followed by BCMA BsAb (21%, n=67) and combination BsAb (2%, n=6). The remaining 39% received varied treatments with no clear predominant regimen, including 6 pts with CAR-T. Similarly, BsAb were used in 49% (n=83) of pts with 2nd sLOT including GPRC5D BsAb (29%, n=49), BCMA BsAb (17%, n=29) and combination BsAb (n=5), while other treatments were varied and 8 pts received 2nd CAR-T.
ORR/VGPR rates with 1st sLOT were 39%/26% and 42%/26% with 2nd sLOT. Median PFS-1 was 4.6 mo and median PFS-2 was 4.8 mo. BsAb yielded the best efficacy and switching target from BCMA to GPRC5D produced superior outcomes. ORR with 1st sLOT was 54% for GPRC5D BsAb, 37% for BCMA BsAb and 25% for others combined. Median PFS-1 was 6 mo with GPRC5D BsAb, 4.7 mo with BCMA BsAb, 0.9-4.4 mo for others (p<0.001). Pts with relapse <6 mo or 6-12 mo after cilta-cel had significantly worse PFS-1 vs. relapse >12 mo (2.8 vs 2.8 vs 11.6 mo, p<0.001). For pts relapsing within 12 mo of cilta-cel, median PFS-1 with GPRC5D vs BCMA BsAb was 5.1 vs 1.6 mo (p=0.03) and for those relapsing after 12 mo, PFS-1 was 11.6 vs 9.5 mo, p=0.78, respectively. On multivariable analysis for PFS-1 adjusting for timing of relapse (<6, 6-12,>12mo), extramedullary disease, high-risk cytogenetics, and functional high-risk, BCMA BsAb had trend for inferior PFS-1 vs GPRC5D BsAb (HR 1.5, 95% CI 0.95-2.35, p=0.08), while alkylating chemotherapy had the worst outcomes (HR 4.5, 95% CI 2.6-7.7, p<0.001), likely reflecting disease burden.
Similar trends were seen for 2nd sLOT, though no significant PFS-2 difference emerged between BCMA and GPRC5D BsAb, likely confounded by intervening 1st sLOT therapy. ORR with 2nd sLOT was 67% for GPRC5D BsAb, 35% for BCMA BsAb, and 31% for all others. For the sub-group progressing after cilta-cel and BsAb as 1st sLOT (n=78), median PFS-2 was 4.5 mo. PFS-2 for post cilta-cel and BCMA BsAB relapse (n=26) was 5.6 mo and for post cilta-cel and GPRC5D BsAb relapse (n=52) was 4.2 mo, identifying a population of significant unmet need.
For 14 pts receiving CAR-T as 1st or 2nd sLOT, PFS-1 was 5.6 mo with CAR-T as 1st sLOT (n=6) and 8.2 mo with CAR-T as 2nd sLOT (n=8).
Conclusions: We describe post-relapse outcomes in a large cohort of pts treated with cilta-cel, predominantly in late LOT. Early relapse after cilta-cel portends the worst subsequent PFS. BsAb appear to be the favored treatment modality at relapse with best ORR and PFS, and target switching to GPRC5D yields the best PFS-1, especially for pts relapsing <12 mo after cilta-cel. We further define a population of unmet need: relapses after both cilta-cel and BsAb, with median PFS-2 of only 4.2-5.6 mo. These findings support prioritizing BsAb as sLOT after cilta-cel relapse, particularly with target antigen switching, and highlight an urgent need for novel strategies for relapses following both CAR-T and BsAb therapy. These data can guide clinical decision-making and inform future trial design in this setting.
DISCLOSURES
Surbhi Sidana, MD: Janssen, BMS, Legend, Arcellx, Kite, Genentech, Roche, Sanofi, Pfizer, Takeda, Kite, Bioline, AbbVie, Cell Centric, Caribou, Regeneron and Eli Lilly (conuslting). Research funding to insitution: Janssen, BMS, Kite, Kelonia, Novartis, Abbvie - Consultancy (Includes expert testimony)